PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES

Cancer is one of the main causes of morbidity and mortality worldwide. Glioblastoma-GBM is the most malignant variant of intrinsic glial brain tumors. The treatments available entailed surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug r...

Descripción completa

Detalles Bibliográficos
Autores: Domínguez-Martí, E. M., Magalhães, Mariana, Sitarek, P., Díaz-Lanza, A. M., Gómez, Ana M., Efferth, T., Cabral, C., Rijo, P.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/336137
Acceso en línea:http://hdl.handle.net/10261/336137
Access Level:acceso abierto
Palabra clave:Glioblastoma
Lamiaceae
Plectranthus
Diterpenes
Royleanones
id ES_4ba052f863947bbca15a8a0ddafff15d
oai_identifier_str oai:digital.csic.es:10261/336137
network_acronym_str ES
network_name_str España
repository_id_str
spelling PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENESDomínguez-Martí, E. M.Magalhães, MarianaSitarek, P.Díaz-Lanza, A. M.Gómez, Ana M.Efferth, T.Cabral, C.Rijo, P.GlioblastomaLamiaceaePlectranthusDiterpenesRoyleanonesCancer is one of the main causes of morbidity and mortality worldwide. Glioblastoma-GBM is the most malignant variant of intrinsic glial brain tumors. The treatments available entailed surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug resistance, severe side effects, relapse and reduced survival. Therefore, new therapeutic approaches are needed to overcome these problems [1]. Natural products are an important source of bioactive lead molecules. The genus Plectranthus (Lamiaceae family) is known to be rich in diterpenes abietane-type royleanones (such as 7α-acetoxy-6β-hydroxyroyleanone (Roy), 7β,6β-dihydroxyroyleanone (DiRoy), 6,7-dehydroroyleanone (DeRoy) and Parviflorone D (ParvD)) which possess, among others, antitumoral properties. The cytotoxic effect of these royleanones is due to their pro-apoptotic nature, which results, for example, in exert their activity in primary H7PX glioma cells by DNA double-strand breaks and G2/M cell cycle arrest [2]. Among the mentioned royleanones, Roy and DiRoy are frequently found in the extracts of the species P. hadiensis var. hadiensis Schweinf. and P. grandidentatus Gürke. Recently, we described the bioguided isolation of compounds from the acetonic extract of P. hadiensis stems and investigated the in vitro antiglioblastoma activity of the extract and its isolated constituents. After extraction, six fractions were obtained. Fractions V and III showed the highest antioxidant and antimicrobial activities. None of the fractions were toxic in the Artemia salina assay. It was isolated the abietane-type diterpenes Roy and DiRoy, which was also in agreement with the HPLC-DAD profile of the extract. The antiproliferative activity evaluation by Alamar blue assay evidenced that after 48 h treatment, Roy exerted strong antiproliferative/cytotoxic effects against tumor cells with low IC values among the different glioblastoma cell lines (U87, A172, U118, U373 and H4). Moreover, it was synthesized a new fluorescence derivative to evaluate the biodistribution of Roy. The uptake of BODIPY-7α-acetoxy-6β-hydroxyroyleanone by GB cells was associated with increased intracellular fluorescence, supporting the antiproliferative effects of Roy [3]. In conclusion, Roy is a promising lead compound to generate semisynthetic derivatives in order to its potential to be used as Active Pharmaceutical Ingredient (API) to develop new pharmaceutical formulations. Further studies should be performed to unveil the mechanism of action of Roy active against GB, which appears to be due to its accumulation in cytoplasmic vesicles and to the induction of mitochondria dependent intrinsic pathway apoptosis.This work was supported by FCT-Foundation for Science and Technology, through UIDB/04567/2020 and UIDP/04567/2020.Peer reviewedConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2023202320232023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/336137reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.29228/jrp.381Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3361372026-05-22T06:33:51Z
dc.title.none.fl_str_mv PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
title PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
spellingShingle PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
Domínguez-Martí, E. M.
Glioblastoma
Lamiaceae
Plectranthus
Diterpenes
Royleanones
title_short PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
title_full PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
title_fullStr PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
title_full_unstemmed PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
title_sort PLECTRANTHUS: FROM TRADITIONAL MEDICINE TO BRAIN TUMOR THERAPY WITH DITERPENES
dc.creator.none.fl_str_mv Domínguez-Martí, E. M.
Magalhães, Mariana
Sitarek, P.
Díaz-Lanza, A. M.
Gómez, Ana M.
Efferth, T.
Cabral, C.
Rijo, P.
author Domínguez-Martí, E. M.
author_facet Domínguez-Martí, E. M.
Magalhães, Mariana
Sitarek, P.
Díaz-Lanza, A. M.
Gómez, Ana M.
Efferth, T.
Cabral, C.
Rijo, P.
author_role author
author2 Magalhães, Mariana
Sitarek, P.
Díaz-Lanza, A. M.
Gómez, Ana M.
Efferth, T.
Cabral, C.
Rijo, P.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Glioblastoma
Lamiaceae
Plectranthus
Diterpenes
Royleanones
topic Glioblastoma
Lamiaceae
Plectranthus
Diterpenes
Royleanones
description Cancer is one of the main causes of morbidity and mortality worldwide. Glioblastoma-GBM is the most malignant variant of intrinsic glial brain tumors. The treatments available entailed surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug resistance, severe side effects, relapse and reduced survival. Therefore, new therapeutic approaches are needed to overcome these problems [1]. Natural products are an important source of bioactive lead molecules. The genus Plectranthus (Lamiaceae family) is known to be rich in diterpenes abietane-type royleanones (such as 7α-acetoxy-6β-hydroxyroyleanone (Roy), 7β,6β-dihydroxyroyleanone (DiRoy), 6,7-dehydroroyleanone (DeRoy) and Parviflorone D (ParvD)) which possess, among others, antitumoral properties. The cytotoxic effect of these royleanones is due to their pro-apoptotic nature, which results, for example, in exert their activity in primary H7PX glioma cells by DNA double-strand breaks and G2/M cell cycle arrest [2]. Among the mentioned royleanones, Roy and DiRoy are frequently found in the extracts of the species P. hadiensis var. hadiensis Schweinf. and P. grandidentatus Gürke. Recently, we described the bioguided isolation of compounds from the acetonic extract of P. hadiensis stems and investigated the in vitro antiglioblastoma activity of the extract and its isolated constituents. After extraction, six fractions were obtained. Fractions V and III showed the highest antioxidant and antimicrobial activities. None of the fractions were toxic in the Artemia salina assay. It was isolated the abietane-type diterpenes Roy and DiRoy, which was also in agreement with the HPLC-DAD profile of the extract. The antiproliferative activity evaluation by Alamar blue assay evidenced that after 48 h treatment, Roy exerted strong antiproliferative/cytotoxic effects against tumor cells with low IC values among the different glioblastoma cell lines (U87, A172, U118, U373 and H4). Moreover, it was synthesized a new fluorescence derivative to evaluate the biodistribution of Roy. The uptake of BODIPY-7α-acetoxy-6β-hydroxyroyleanone by GB cells was associated with increased intracellular fluorescence, supporting the antiproliferative effects of Roy [3]. In conclusion, Roy is a promising lead compound to generate semisynthetic derivatives in order to its potential to be used as Active Pharmaceutical Ingredient (API) to develop new pharmaceutical formulations. Further studies should be performed to unveil the mechanism of action of Roy active against GB, which appears to be due to its accumulation in cytoplasmic vesicles and to the induction of mitochondria dependent intrinsic pathway apoptosis.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/336137
url http://hdl.handle.net/10261/336137
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://dx.doi.org/10.29228/jrp.381
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407572962836480
score 15,812429

Similares en LA Referencia